As some of the world’s most important medicines have shifted from simple chemicals to complex biologics, a new category of competitor has emerged: the biosimilar. Understanding what biosimilars are matters because they sit at the intersection of hard science, regulation and healthcare economics — and because they are frequently, and incorrectly, described as “generic biologics.” This explainer is educational and does not offer medical advice; any treatment decision belongs with a qualified clinician.
What is a biosimilar?
A biosimilar is a biologic medicine that has been shown to be highly similar to an already-approved biologic — known as the reference product — with no clinically meaningful differences in safety, purity and potency. The key phrase is “highly similar,” not “identical.” That is not a marketing softener; it reflects the underlying biology, and regulators are explicit about it. The US Food and Drug Administration (fda.gov) and the European Medicines Agency (ema.europa.eu) both define biosimilars in these terms and run dedicated approval pathways for them.
Why can’t a biosimilar be identical?
The answer lies in what biologics are. Conventional “small-molecule” drugs are relatively simple chemicals with well-defined structures; a generic version can be manufactured as an exact chemical copy of the original. Biologics are different in kind. They are large, complex molecules — such as therapeutic proteins and antibodies — produced inside living cells. Their size, three-dimensional structure and natural micro-variations mean that no two production processes yield molecules that are perfectly identical, and even successive batches of the original biologic vary slightly within controlled limits.
Because the medicine cannot be copied atom-for-atom, the regulatory goal shifts. Instead of proving chemical sameness, a biosimilar developer must demonstrate biosimilarity: that any differences from the reference product are not clinically meaningful and that the product meets the same rigorous standards. The table below summarises the contrast that trips up most people.
| Attribute | Small-molecule generic | Biosimilar |
|---|---|---|
| Reference product type | Chemical drug | Biologic medicine |
| Molecule size / complexity | Small, simple | Large, complex |
| How it is made | Chemical synthesis | Grown in living cells |
| Relationship to original | Can be identical copy | Highly similar, not identical |
| Approval basis | Demonstrate bioequivalence | Demonstrate biosimilarity (totality of evidence) |
How is a biosimilar developed and approved?
Biosimilar approval rests on what regulators call a “totality of the evidence.” Rather than repeating the full clinical development that established the reference product, the developer builds a comparative case that the two are highly similar. This typically proceeds in layers:
- Analytical characterisation. Extensive laboratory comparison of the biosimilar and reference molecules — structure, purity and physicochemical properties. This is the foundation, and it is far more detailed than the comparison required for a generic.
- Functional studies. Tests of biological activity to confirm the molecules behave the same way in relevant assays.
- Non-clinical and clinical studies. Studies including pharmacokinetics and, where needed, comparative clinical work to confirm there are no clinically meaningful differences in safety, efficacy and immunogenicity (the potential to provoke an immune response).
The emphasis differs from an original biologic’s development: the aim is to confirm similarity to something already proven safe and effective, not to establish benefit from scratch. Regulators such as the FDA and EMA publish detailed scientific guidelines describing what evidence they expect, and both maintain public information resources — the FDA’s Purple Book lists licensed biologics and biosimilars, for example.
What does “interchangeable” mean?
Terminology here varies by jurisdiction, and precision matters. In the United States, the law that created the biosimilar pathway (the Biologics Price Competition and Innovation Act, part of wider health reform) allows a biosimilar to seek an additional designation of interchangeability by meeting further requirements. An interchangeable product may, depending on state law, be substituted for the reference product at the pharmacy without the prescriber’s involvement. Importantly, interchangeability is a regulatory and legal status about substitution practice — it is not a statement that interchangeable biosimilars are somehow “better” than other biosimilars, all of which must meet the same core standard of no clinically meaningful differences. Other regions handle substitution differently, and rules continue to evolve.
Why do biosimilars matter to healthcare markets?
Biologics are among the most clinically valuable and most expensive medicines, used in areas such as cancer, autoimmune and inflammatory conditions. When a reference biologic loses its market exclusivity, biosimilars can enter and introduce competition. In structural terms, this tends to broaden the range of suppliers, can support wider patient access, and influences healthcare budgets and payer decisions. The dynamics are more complex than in the generics market, however, because manufacturing is harder, development is costlier, and physician and patient familiarity plays a larger role in uptake.
These forces link biosimilars tightly to the wider system that produces and delivers them — see our companion explainer on how the pharmaceutical supply chain works, since biologics also depend on robust cold-chain logistics to remain stable.
How do analysts study the biosimilar segment?
Because biosimilar uptake varies so much by product, disease area and country, careful analysis avoids a single blended figure. Instead, analysts segment by therapy area, by individual reference molecule and its exclusivity timeline, by manufacturer type, and by region — since regulatory pathways, substitution rules and reimbursement all differ. They then reason qualitatively about drivers (exclusivity expiries, payer pressure for access and affordability, prescriber confidence) and headwinds (development cost and complexity, manufacturing barriers, and market-adoption dynamics). This segment-first discipline is the same one described in our guides to market sizing and research methodology, and it is why the credible answer to “how big is the biosimilar market?” is usually a structured breakdown rather than a headline claim. Further primers sit in the healthcare and life sciences hub.
The bottom line
A biosimilar is a highly similar — not identical — version of an approved biologic, developed and authorised through a rigorous, science-based regulatory pathway designed to confirm there are no clinically meaningful differences from the reference product. It is not a generic, because biologics cannot be copied exactly. Understood correctly, biosimilars are a carefully governed way to bring competition to complex medicines. As always, this is general information, not medical advice, and clinical choices should be made with a healthcare professional.
